Screener
Altimmune ALT Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Loss from operations | (24,244) | (21,815) |
| Other income (expense): | ||
| Interest expense | (1,068) | (1) |
| Interest income | 2,901 | 1,545 |
| Other income (expense), net | (152) | 15 |
| Total other income (expense), net | 1,681 | 1,559 |
| Net loss before income taxes | (22,563) | (20,256) |
| Income tax expense (benefit) | — | (681) |
Item 1. Financial Statements
FAQ
- What is Altimmune's interest income?
- Altimmune (ALT) reported interest income of $2.9M in Q1 2026.
- How has Altimmune's interest income changed year-over-year?
- Altimmune's interest income increased by 87.8% year-over-year, from $1.55M to $2.9M.
- What is the long-term trend for Altimmune's interest income?
- Over 4 years (2021 to 2025), Altimmune's interest income has grown at a 146.9% compound annual growth rate (CAGR), from $203K to $7.54M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Altimmune's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude